Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).

被引：0
|
作者：
Ruff, P [1 ]
Moodley, SD [1 ]
Rapoport, BL [1 ]
Chasen, MR [1 ]
Jacobs, C [1 ]
Hacking, D [1 ]
Voroblof, DA [1 ]
机构：
[1] S African Caelyx Investigators Grp, Johannesburg, South Africa
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306P
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [41] Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors
    Mavroudis, D
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Samonis, G
    Georgoulias, V
    ONCOLOGY, 2002, 62 (03) : 216 - 222
  • [42] Phase II pilot study of Caelyx (doxorubicin HCl, pegylated liposomal) in patients with inoperable head and neck squamous cell cancer.
    Harrington, K
    Stewart, S
    Harrison, D
    Whittaker, J
    Elliott, P
    BRITISH JOURNAL OF CANCER, 1998, 78 : 34 - 34
  • [43] First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer:: a multicentre phase II study
    Vorobiof, DA
    Rapoport, BL
    Chasen, MR
    Slabber, C
    McMichael, G
    Eek, R
    Mohammed, C
    BREAST, 2004, 13 (03): : 219 - 226
  • [44] Liposomal Doxorubicin (Caelyx) in advanced pretreated Soft Tissue Sarcomas: A phase II study of the Italian Sarcoma Group (ISG)
    Toma, S
    Tucci, A
    Villani, G
    Carteni, G
    Spadini, N
    Palumbo, R
    ANTICANCER RESEARCH, 2000, 20 (1B) : 485 - 491
  • [45] Pegylated-liposomal doxorubicin (Caelyx) plus weekly docetaxel (Taxotere): A phase I and pharmacokinetic study.
    Briasoulis, E
    Rammou, D
    Tzamakou, E
    Karavasilis, V
    Ioannidou, A
    Soulti, K
    Pavlidis, N
    ANNALS OF ONCOLOGY, 2000, 11 : 134 - 134
  • [46] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Evangelos Briasoulis
    Vasilis Karavasilis
    Eleftheria Tzamakou
    Dimitra Rammou
    Kali Soulti
    Christina Piperidou
    Nicholas Pavlidis
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 452 - 457
  • [47] Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:: a study by the EORTC Soft Tissue and Bone Sarcoma Group
    Judson, I
    Radford, JA
    Harris, M
    Blay, JY
    van Hoesel, Q
    le Cesne, A
    van Oosterom, AT
    Clemons, MJ
    Kamby, C
    Hermans, C
    Whittaker, J
    di Paola, ED
    Verweij, J
    Nielsen, S
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) : 870 - 877
  • [48] Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer
    Grazia, Artioli
    Simone, Mocellin
    Lucia, Borgato
    Alessandro, Cappetta
    Fernando, Bozza
    Giorgio, Zavagno
    Stefania, Zovato
    Alberto, Marchet
    Davide, Pastorelli
    ANTICANCER RESEARCH, 2010, 30 (09) : 3817 - 3821
  • [49] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Briasoulis, E
    Karavasilis, V
    Tzamakou, E
    Rammou, D
    Soulti, K
    Piperidou, C
    Pavlidis, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) : 452 - 457
  • [50] Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer
    Eva Perez-Lopez, Maria
    Curiel, Teresa
    Garcia Gomez, Jesus
    Jorge, Monica
    ANTI-CANCER DRUGS, 2007, 18 (05) : 611 - 617
12345